Subretinal fibrosis occurrence according to macular neovascularisation subtypes in neovascular age-related macular degeneration

被引:0
|
作者
Lenhof, Scott [1 ]
Kodjikian, Laurent [1 ,2 ,3 ]
Gascon, Pierre [4 ,5 ]
Gadiollet, Etienne [1 ]
Feldman, Audrey [6 ]
De Bats, Flore [7 ]
Wolff, Benjamin [8 ]
Pradat, Pierre [9 ]
Mathis, Thibaud [1 ,2 ,3 ]
机构
[1] Croix Rousse Univ Hosp, Hosp Civils Lyon, Ophthalmol Dept, Lyon, France
[2] Univ Claude Bernard Lyon 1, Lab Multimat & Interfaces, UMR CNRS 5615, F-69622 Villeurbanne, France
[3] Univ Claude Bernard Lyon 1, Lyon, France
[4] Aix Marseille Univ, Hop Nord, Ophthalmol Dept, Marseille, France
[5] Aix Marseille Univ, Timone Neurosci Inst, Marseille, France
[6] Hop Prive Est Lyonnais, LEO Eye Ctr, St Priest, France
[7] Clin Val Ouest, Pole Vis, Ecully, France
[8] Maison Rouge Eye Ctr, Strasbourg, France
[9] Croix Rousse Univ Hosp, Hosp Civils Lyon, Clin Res Ctr, Lyon, France
关键词
age-related macular degeneration; fibrosis; functional impact; incidence; macular neovascularisation; risk factors; VISUAL-ACUITY; FIBROTIC SCAR; RISK-FACTORS; IDENTIFICATION; EYES; QUANTIFICATION; PREVALENCE; ATROPHY; LESIONS;
D O I
10.1111/aos.16759
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To assess subretinal fibrosis (SF) occurrence in neovascular age-related macular degeneration (nAMD), according to macular neovascularisation (MNV) subtypes. Methods: A Retrospective national multi centre cohort study included eyes with naive nAMD. Main outcome measures were, according to MNV subtypes, cumulative incidence for SF, risk factors, and best corrected visual acuity (BCVA) for 36 months. Results: Four hundred and twenty eyes were included. Cumulative incidence of SF was 34.3% at 1 year, 39.0% at 2 years and 50.6% at 3 years. In multivariable analysis, Type 2 and mixed type 1 and 2 MNV were associated (p < 0.001) with a more frequent and rapid development of SF (respectively 85.5% and 81.0% at 1 year, then 95.8% and 93.1% at 3 years) than Types 1 and 3 (respectively 11.3% and 3.6% at 1 year, then 22.9% and 12.7% at 3 years). In Type 2 and mixed type 1 and 2 MNV combined, at baseline a worse BCVA (p = 0.02) and a higher maximal subretinal hyperreflective material (SHRM) thickness (p = 0.005) were associated with SF development at 3 years. In Type 1 MNV, the presence at baseline of intraretinal fluid (IRF) (p = 0.007) or SHRM (p < 0.001) and a higher percentage of visits with IRF (p < 0.001) or with SHRM (p < 0.001) were associated with SF occurrence. For Type 3 MNV, only a higher percentage of visits with SHRM (p = 0.001) was associated with SF. Including all MNV subtypes, eyes with a worse BCVA at baseline were associated with SF development (p < 0.001). Conversely, presence of SF at 3 years was associated with a worse baseline BCVA (p < 0.001). Conclusion: Occurrence of SF differs when considering apart MNV subtypes.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Subretinal fibrosis in neovascular age-related macular degeneration: current concepts, therapeutic avenues, and future perspectives
    Louis Tenbrock
    Julian Wolf
    Stefaniya Boneva
    Anja Schlecht
    Hansjürgen Agostini
    Peter Wieghofer
    Günther Schlunck
    Clemens Lange
    Cell and Tissue Research, 2022, 387 : 361 - 375
  • [32] The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
    Xu, Heping
    Yi, Caijiao
    Chen, Mei
    CURRENT OPINION IN PHARMACOLOGY, 2024, 76
  • [33] Macular atrophy development in neovascular age-related macular degeneration
    Calugaru, Dan
    Calugaru, Mihai
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2022, 32 (01) : NP307 - NP308
  • [34] Pegaptanib for neovascular age-related macular degeneration
    Gragoudas, ES
    Adamis, AP
    Cunningham, ET
    Feinsod, M
    Guyer, DR
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (27): : 2805 - 2816
  • [35] Management of neovascular age-related macular degeneration
    Schmidt-Erfurth, Ursula M.
    Pruente, Christian
    PROGRESS IN RETINAL AND EYE RESEARCH, 2007, 26 (04) : 437 - 451
  • [36] Ranibizumab for neovascular age-related macular degeneration
    Rosenfeld, Philip J.
    Brown, David M.
    Heier, Jeffrey S.
    Boyer, David S.
    Kaiser, Peter K.
    Chung, Carol Y.
    Kim, Robert Y.
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14): : 1419 - 1431
  • [37] Imaging in Neovascular Age-Related Macular Degeneration
    Gess, Adam J.
    Fung, Anne E.
    Rodriguez, Jorge G.
    SEMINARS IN OPHTHALMOLOGY, 2011, 26 (03) : 225 - 233
  • [38] Aflibercept for neovascular age-related macular degeneration
    Sarwar, Salman
    Clearfield, Elizabeth
    Soliman, Mohamed Kamel
    Sadiq, Mohammad Ali
    Baldwin, Andrew J.
    Hanout, Mostafa
    Agarwal, Aniruddha
    Sepah, Yasir J.
    Do, Diana V.
    Quan Dong Nguyen
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (02):
  • [39] Radiotherapy for neovascular age-related macular degeneration
    Evans, Jennifer R.
    Sivagnanavel, Vasuki
    Chong, Victor
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (05):
  • [40] Bevacizumab for Neovascular Age-Related Macular Degeneration
    Silva, Aline
    Furlan, Luiz
    Elias, Flavia
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 75 - 76